Clinical trials: Cholangiocarcinoma Cancer
Cancer of Liver
Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma
Our long-term working hypothesis is that if 3-D radiation is combined with the effect of capecitabine one hopes to see improved and durable tumor response and survival with acceptable toxicity.
- Trial name
- NCT00216437
- Testing
- Capecitabine (Xeloda)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- James A. Haley Veterans Administration Hospital
Pancreatic Cancer, Cholangiocarcinoma
Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cancer
Based on the cell free nucleic acid analysis information of blood samples, the results of microbiome and metabolite analysis of stool and urine samples of pancreatic cancer and bile duct cancer patients, the clinical correlations…
- Conditions
- Pancreatic Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT05596370
- Testing
- cell free DNA in blood and urine, metabolite/microbiome in urine and stool
- Where
- 2 sites in South Korea
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Pancreatic Cancer, Bile Duct Cancer
The Comparison of Miniinvasive and Open Pancreaticoduodenectomy for Cancer Pancreaticobiliary Zone
The Comparison of Miniinvasive and Open Pancreaticoduodenectomy for Cancer Pancreaticobiliary Zone
- Conditions
- Pancreatic Cancer, Bile Duct Cancer, Ampulla of Vater Cancer
- Trial name
- NCT04763642
- Testing
- pancreaticoduodenectomy
- Where
- Russia
- Volunteers
- 320 people
- Sponsor
- State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital
Advanced Malignancies That Harbor IDHR132 Mutations
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
- Trial name
- NCT02381886
- Testing
- IDH305
- Where
- 16 sites in United States, Australia and 6 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Intrahepatic Cholangiocarcinoma
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma.
- Trial name
- NCT04078230
- Testing
- Extend LymphAdenectomy
- Where
- 13 sites in United States, China
- Volunteers
- 168 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cholangiocarcinoma, Gallbladder Cancer
Avastin and Tarceva for Upper Gastrointestinal Cancers
Erlotinib and bevacizumab have shown activity individually, as single drugs, or in combination with chemotherapy in upper gastro-intestinal cancers, including esophageal and gastro-esophageal adenocarcinomas, gastric cancer and…
- Trial name
- NCT00350753
- Testing
- Erlotinib and bevacizumab
- Where
- 3 sites in Denmark
- Volunteers
- 126 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Perihilar Cholangiocarcinoma, Jaundice, Obstructive
Endoscopic Versus Radiologic Biliary Drainage for Perihilar Malignant Obstruction
This retrospective monocentric study aims at comparing multimodality endoscopic biliary drainage versus percutaneous radiologic biliary drainage in case of perihilar malignant obstruction.
- Trial name
- NCT05078801
- Testing
- Endoscopic drainage, Percutaneous transhepatic biliary drainage
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Cholangiocarcinoma, Bile Duct Carcinoma
Clinico-demographic Profile of the Patient With Pancreaticobiliary Malignancy Undergoing ERCP in a Tertiary Care Center of Nepal
Background Pancreaticobiliary malignancy (PBM) is a group of cancers affecting pancreas and bile duct. The diagnosis is often late and with fatal outcomes.
- Conditions
- Cholangiocarcinoma, Bile Duct Carcinoma, Endoscopic Retrograde Cholangio-Pancreatography, Pancreatic Neoplasms
- Trial name
- NCT06888401
- Testing
- ERCP
- Where
- Nepal
- Volunteers
- 597 people
- Sponsor
- Kathmandu University School of Medical Sciences
Haemangioma, Metastases
Quantitative Real-time Ultrasound Elastography for Characterisation of Liver Tumors
Shear Wave Elastography (SWE™) is a quantitative elastography method for measuring tissue stiffness. The difference in stiffness between benign and malignant tumors has been demonstrated by other elastography methods (acoustic…
- Conditions
- Haemangioma, Metastases, Cholangiocellular Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT02156700
- Testing
- Shear wave elastography
- Where
- Croatia
- Volunteers
- 196 people
- Sponsor
- University Hospital Dubrava
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (ICC)
An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
Primary liver cancer, mainly including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), represents the third leading cause of cancer-related mortality.
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (ICC), Primary Liver Cancer
- Trial name
- NCT07101237
- Testing
- Multi-modal ultrasonic imaging system for liver cancer
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Peking Union Medical College Hospital
Bile Duct Cancer
Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours
Bile duct tumours are rare. They are the 6th most common type of digestive cancer. Their therapeutic management is complex and must be multidisciplinary in nature.
- Trial name
- AMEBICA (NCT02591030)
- Testing
- GEMCIS, mFolfirinox
- Where
- 42 sites in France
- Volunteers
- 191 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Peritoneal Carcinomatosis, Peritoneal Metastases
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase…
- Conditions
- Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Small Bowel Cancer
- Trial name
- PIPAC-NAL-IRI (NCT05277766)
- Testing
- PIPAC with Nal-IRI
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- University Hospital, Ghent
Pancreatic Cancer, Liver Cancer
Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program
Major surgery is a stressful procedure; good recovery after surgery is important to patients and their doctors. Studies done at the McGill University Health Centre (MUHC) with cancer patients awaiting surgery have shown that…
- Conditions
- Pancreatic Cancer, Liver Cancer, Bile Duct Cancer, Hepatobiliary Cancer
- Trial name
- NCT03475966
- Testing
- Exercise, Nutrition, Relaxation techniques
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00033540
- Testing
- capecitabine, gemcitabine hydrochloride
- Where
- 112 sites in United States
- Volunteers
- 57 people
- Sponsor
- SWOG Cancer Research Network
Cholangiocarcinoma
Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma
Endobiliary radiofrequency ablation (RFA) with biliary stent has been reported to be a beneficial treatment option for palliation of malignant biliary strictures.
- Trial name
- NCT02592538
- Testing
- radiofrequency ablation, S-1, Stent
- Where
- China
- Volunteers
- 66 people
- Sponsor
- First People's Hospital of Hangzhou
Nonresectable Bile Duct Cancer
Prospective Evaluation of the Ablation Therapy With Bipolar Radio Frequency for Nonresectable Bile Duct Cancer
90 % of the patients with bile duct cancer are not justifiable of a surgical resection with curative aim for oncologic reasons ( metastatic extensions), for reasons of resectability (canalar extension, vascular) or still for…
- Trial name
- RFA-BILIAIRE (NCT03679338)
- Testing
- Ablation Therapy
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Institut Paoli-Calmettes
Colorectal Neoplasms, Gastric Neoplasms
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Background: Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors.
- Conditions
- Colorectal Neoplasms, Gastric Neoplasms, Cholangiocarcinoma, Bile Duct Cancer
- Trial name
- NCT01915225
- Where
- United States
- Volunteers
- 1,800 people
- Sponsor
- National Cancer Institute (NCI)
Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
This study focused on exploring new comprehensive treatment strategies for patients with unresectable combined hepatocellular-cholangiocarcinoma, classifying patients with CHC subtypes based on the combination of artificial…
- Conditions
- Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
- Trial name
- NCT06849180
- Testing
- Interventional therapies combined with or without systemic drugs
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Zhongda Hospital
Intrahepatic Cholangiocarcinoma
Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma
To explore the objective response rate and safety of toripalimab combined with Gemox in the first-line treatment of progressive, metastatic or unresectable advanced ICC.
- Trial name
- NCT04961788
- Testing
- Gemox combimed PD1 antibody
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Solid Cancers
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are.
- Trial name
- NCT07186842
- Testing
- BNT329, CA19-9-targeting monoclonal antibody
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 245 people
- Sponsor
- BioNTech SE